News Releases

Date Title  
Toggle Summary Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif. , March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Prices $130.0 Million Public Offering of Common Stock
MENLO PARK, Calif. , March 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
- All three doses of lebrikizumab met primary endpoint with statistical significance - Lebrikizumab was well-tolerated; safety profile consistent with prior studies - Efficacy and safety profile support advancement into Phase 3; planned by end of 2019 - Conference call and webcast today at 8:30
Toggle Summary Dermira to Present at the Cowen and Company 39th Annual Health Care Conference
MENLO PARK, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis
Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary hyperhidrosis   New analysis from ATMOS-1 and ATMOS-2 Phase 3 studies illustrates efficacy across broad range of patient populations  
Toggle Summary Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 million Over 14,500 prescriptions for QBREXZA written in first three months of launch Secured QBREXZA coverage for approximately 76% of total U.S. commercial lives Entered into option and license agreement with Almirall for rights to
Toggle Summary Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting
MENLO PARK, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced
Toggle Summary Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis
- Study will assess the impact of QBREXZA treatment on sweat severity in patients with primary palmar hyperhidrosis - Results will inform potential development plans for QBREXZA in primary palmar hyperhidrosis - Findings from the study are expected in the second half of 2019 MENLO PARK, Calif.
Toggle Summary Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference
MENLO PARK, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019
MENLO PARK, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will report
Toggle Summary Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
-  Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe -  Dermira to receive an option fee of $30 million -  Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data